Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: Pyrotinib
Sponsor: First Affiliated Hospital Xi'an Jiaotong University